| Prev Close | 3.27 |
| Open | 3.31 |
| Day Low/High | 3.22 / 3.42 |
| 52 Wk Low/High | 2.48 / 21.00 |
| Volume | 32.82K |
| Avg Volume | 227.70K |
| Exchange | NASDAQ |
| Shares Outstanding | 23.72M |
| Market Cap | 78.27M |
| EPS | -3.00 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
These 5 Stocks Are Breaking Out
Here's a technical look at how to trade five stocks that are within range of triggering big breakouts.
5 Stocks With Big Insider Buying
Insiders at these companies have been scooping up shares of their own stock lately.
Here’s A Reason aTyr Pharma (LIFE) Stock is Rising Today
Shares of aTyr Pharma (LIFE) are climbing late Tuesday afternoon as BMO Capital began coverage of the stock with a ‘market perform’ rating and $8 price target.
5 Stocks Poised for Breakouts
These stocks look ready to break out and trade higher from current levels.
ATyr Provides Corporate Update And Outlook For 2016
Data for Phase 1b/2 Clinical Trial of Resolaris in Adult FSHD Patients Expected at Approximately the End of First Quarter 2016
Oversold Conditions For aTyr Pharma (LIFE)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Publication In Nature Demonstrates Physiocrine Genetic Mutation Disrupts A Key Signaling Pathway In Neuronal Biology
aTyr Sponsored Research For New Target For Rare Hereditary Peripheral Neuropathies
ATyr Pharma Doses First Patient In Long-Term Safety Extension Study Of Resolaris™ For Treatment Of Adult Patients With FSHD
Physiocrine-Based Therapy Harnesses Natural Immunomodulation Pathway to Address Rare Genetic Muscular Dystrophy